SCHEMBL2163601

SCHEMBL2163601

CCC(Cl)Oc1cc2nnnc(Nc3cc(Cl)cc(Cl)c3)c2cc1OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 10/20 0.42
SRC P12931 8/20 0.42
KDM4E B2RXH2 3/20 0.42
MAPT P10636 2/20 0.42
MAPK1 P28482 2/20 0.42
FBP1 P09467 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.42
GMNN O75496 1/20 0.42
ABL1 P00519 1/20 0.42
LMNA P02545 1/20 0.42
RAF1 P04049 1/20 0.42
TP53 P04637 1/20 0.42
CYP1A2 P05177 1/20 0.42
GLA P06280 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
NFKB1 P19838 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2163493 0.90 KDR (0.54) EGFRSRCKDM4EMAPTMAPK1
SCHEMBL2165591 0.90 EGFR (0.56) EGFRSRCKDM4EMAPTMAPK1
SCHEMBL2164278 0.88 KDR (0.45) EGFRSRCFBP1KDRLCK
SCHEMBL2163645 0.87 EGFR (0.51) EGFRSRCKDM4EMAPTMAPK1
SCHEMBL2163097 0.86 KDR (0.48) EGFRFBP1KDRFLT1EPHA2
SCHEMBL2163565 0.86 SLC2A1 (0.50) EGFRKDRFLT1LCKERBB2
SCHEMBL2164226 0.86 EGFR (0.58) EGFRFBP1KDRPDGFRBAURKA
SCHEMBL2164524 0.85 EGFR (0.53) EGFRMAPTFBP1TP53KDR
SCHEMBL2164488 0.84 SRC (0.51) EGFRSRCKDM4EMAPTMAPK1
SCHEMBL2163631 0.83 EGFR (0.55) EGFRSRCKDM4EMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349835-B2 Aromatic ring fused triazine derivatives and uses thereof SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2013-01-08 US claimed
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2011-07-28 US claimed
EP-2251332-A1 THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF Shenyang Pharmaceutical University (CN) 2010-11-17 EP claimed
US-8349835-B2 Aromatic ring fused triazine derivatives and uses thereof SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2013-01-08 US disclosed
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2011-07-28 US disclosed
EP-2251332-A1 THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF Shenyang Pharmaceutical University (CN) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF KDR, FLT1, FLT4 EGFR 8/4885SRC 48/4885KDM4E 1755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.